BioAtla Faces Nasdaq Trading Suspension and Potential Delisting

BioAtla ( (BCAB) ) has issued an announcement.

On February 6, 2026, BioAtla, Inc. disclosed that it had received a Nasdaq determination to suspend trading of its common stock, citing the company’s failure to meet the $1.00 minimum bid price and the $2.5 million stockholders’ equity requirement, despite having previously met the alternative market value of listed securities threshold for 69 consecutive trading days. The company has challenged Nasdaq’s handling of its compliance review and a recent policy shift on the use of super-voting stock for reverse stock split approvals, and it has requested immediate review and a stay of the delisting decision by the Nasdaq Listing and Hearing Review Council; absent a stay, BioAtla’s shares are expected to be suspended from Nasdaq on February 10, 2026 and move to OTC quotation under the BCAB ticker, a transition the company warns could materially hurt trading price, liquidity, and shareholders’ ability to transact, with no assurance of a successful appeal or sustained market for the stock.

The most recent analyst rating on (BCAB) stock is a Hold with a $0.18 price target. To see the full list of analyst forecasts on BioAtla stock, see the BCAB Stock Forecast page.

Spark’s Take on BCAB Stock

According to Spark, TipRanks’ AI Analyst, BCAB is a Neutral.

The score is held down primarily by weak financial fundamentals (no TTM revenue, large losses, cash burn, and negative equity) and bearish technicals (price below major moving averages with negative momentum). Offsetting support comes from more constructive clinical/regulatory progress and potential partnering/financing developments, but near-term liquidity and listing/compliance risks remain key overhangs.

To see Spark’s full report on BCAB stock, click here.

More about BioAtla

Average Trading Volume: 2,394,135

Technical Sentiment Signal: Sell

Current Market Cap: $13.44M

See more insights into BCAB stock on TipRanks’ Stock Analysis page.